Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 11112
Sealed predictions
- KIAA0319L in dopamine neurons, braak-0.43 (p 0.243) → +0.05 (p 0.891)receipt 11119
Swarm cases
receipt 11119: KIAA0319L in dopamine neurons, braak
- power
- full sample +0.01 (p 0.969, n 18), 95% CI -0.46 to +0.47. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.00 (p 0.990, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.03 (p 0.901, n 18). could be the mix.
- skeptic
- leave-one-out range -0.11 to +0.14, sign flips 7; without severely affected donors +0.01 (p 0.969, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.67 (p 0.0022, n 18) vs +0.01 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for KIAA0319L in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up KIAA0319L · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.75 p 0.0077 (needs p < 2.0e-4)
Receipts
loading the receipts